Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.32 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20591048 | 1.00 | TMEM97 (0.33) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 | |
| SCHEMBL18341889 | 1.00 | TMEM97 (0.33) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 | |
| SCHEMBL1243886 | 1.00 | TMEM97 (0.33) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 | |
| SCHEMBL5037152 | 1.00 | TMEM97 (0.33) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 | |
| SCHEMBL11667172 | 0.88 | TBXA2R (0.33) | TMEM97SIGMAR1TBXA2RTBXAS1 | |
| SCHEMBL11667553 | 0.84 | MEN1 (0.30) | — | |
| SCHEMBL1274084 | 0.83 | — | — | |
| SCHEMBL13737834 | 0.80 | CA2 (0.40) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 | |
| SCHEMBL6674097 | 0.80 | CA2 (0.40) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 | |
| SCHEMBL13471225 | 0.80 | CA2 (0.40) | TMEM97SIGMAR1TBXA2RTBXAS1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-27 | — | — | US | claimed |
| EP-3313847-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN Laboratories Private Limited (IN) | 2018-05-02 | — | — | EP | claimed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | claimed |
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | MSN LABORATORIES PRIVATE LIMITED (IN) | 2020-04-28 | — | — | US | disclosed |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-12-27 | — | — | US | disclosed |
| EP-3313847-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL](2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN Laboratories Private Limited (IN) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016207907-A1 | PROCESS FOR THE PREPARATION OF [(1 S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1 -(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-12-29 | — | — | WO | disclosed |
| US-7880014-B2 | Angiotensin II receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| EP-1678158-B1 | PROCESS FOR THE PREPARATION OF GLYCERALDEHYDE ACETONIDE | DSM IP ASSETS BV (NL) | 2008-03-26 | — | — | EP | disclosed |
| US-20070129553-A1 | Process for the preparation of glyceraldehyde acetonide | DSM IP ASSETS B.V. (NL) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633390-B2 | Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form | FFAR1, CYP2S1, CYP1B1 | TMEM97 2110/4885SIGMAR1 332/4885TBXA2R 3259/4885 |
| US-20070129553-A1 | Process for the preparation of glyceraldehyde acetonide | CA5A, GCG, CA5B | TMEM97 3650/4885SIGMAR1 1100/4885TBXA2R 1823/4885 |
| US-20180370982-A1 | PROCESS FOR THE PREPARATION OF [(1S,2R)-3-[[(4-AMINOPHENYL)SULFONYL] (2-METHYLPROPYL)AMINO]-2-HYDROXY-1-(PHENYLMETHYL)PROPYL]-CARBAMIC ACID (3R,3AS,6AR)HEXAHYDRO FURO[2,3-B]FURAN-3-YL ESTER AND ITS AMORPHOUS FORM | FFAR1, CYP2S1, FFAR3 | TMEM97 2137/4885SIGMAR1 298/4885TBXA2R 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.